Key result
Injectable anticoagulants remain a valid option for cancer-associated thrombosis despite patient preference for oral therapies.
Why the study?
Due to clinical heterogeneity in patients with cancer, no single universal treatment exists for cancer-associated thrombosis, requiring an understanding of the role of injectables versus oral anticoagulants.
What is the role of injectable anticoagulants compared to oral options in the treatment and prevention of cancer-associated thrombosis?
What is the role of injectable anticoagulants compared to oral options in the treatment and prevention of cancer-associated thrombosis?
This review highlights that despite a general patient preference for oral anticoagulants, injectable anticoagulants remain a crucial and valid option for managing cancer-associated thrombosis due to the complex clinical heterogeneity of these patients.
Answers are grounded in this paper and cite their sources.
Retains injectables as valid options for cancer-associated thrombosis despite oral preference; leaves open individualized selection amid clinical heterogeneity.
Cancer-associated thrombosis (CAT) is a leading cause of death among patients with cancer. CAT can manifest itself as venous thromboembolism (VTE), in the form of deep vein thrombosis or pulmonary embolism, or arterial thromboembolism. The pathophysiology of CAT is complex and depends on cancer-, patient-, treatment- and biomarkers-related factors. Treatment of VTE in patients with cancer is complex and includes three major classes of anticoagulant agents: heparin and its derivatives, e.g., low molecular weight heparins, direct oral anticoagulants (DOACs), and vitamin K inhibitors. Given the tremendous heterogeneity of clinical situations in patients with cancer and the challenges of CAT, there is no single universal treatment option for patients suffering from or at risk of CAT. Initial studies suggested that patients seemed to prefer an anticoagulant that would not interfere with their cancer treatment, suggesting the primacy of cancer over VTE, and favoring efficacy and safety over convenience of route of administration. Recent studies show that when the efficacy and safety aspects are similar, patients prefer the oral route of administration. Despite this, injectables are a valid option for many patients with cancer.
No takes yet. Share an insight, caveat, or question.
Napolitano et al. (2023) conducted a review in Cancer-associated thrombosis. Injectable anticoagulants vs. Oral anticoagulants was evaluated. Injectable anticoagulants remain a valid option for cancer-associated thrombosis, despite patient preference for oral administration when efficacy and safety are similar.
Synapse has enriched 10 related papers. Consider them for comparative context: